Peritoneal Dialysis (PD) is a Renal Replacement Therapy for patients with renal insufficiency that has been used more frequently in recent years. In PD treatment, catheter are used to provide access to the peritoneal cavity, allowing the dialysate to be introduced and removed from the abdomen. The aim of this study is to evaluate the safety and efficacy of long-term treatment with PD catheters (developed by Fresenius Medical Care (FME)) in adult and paediatric patients treated with CAPD or APD. Safety and performance parameters of the catheters will be analyzed, as well as data on PD treatment outcome, such as Peritoneal Clearance and Peritoneal Ultrafiltration.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Signed and dated informed consent for study participation and data submission (by the patient or legal representative for patients under 18) along with investigator/authorized physician signature.
* Patients under 18 who have received age- and maturity-appropriate information per Article 63(2) MDR from trained investigators or team members; minors capable of understanding must also sign the informed consent.
* The investigator must respect the decision of any minor, capable of understanding the information as per Article 63(2) MDR, to decline participation or withdraw from the clinical investigation at any time.
* Ability to understand the nature and requirements of the study.
* Patients with indication for renal replacement therapy, specifically PD (CAPD or APD)
* Patients who began PD using FME catheters within the last 18 months and are either prevalent in PD at study initiation or have switched to HD or undergone transplantation and can consent to data use.
* Incident patients who will begin PD using FME catheters.
Exclusion Criteria:
* Patient or legal representative is not able to give informed consent according to European Medical Device Regulation and corresponding national regulations,
* Previous participation in the same study.
* Life expectancy \< 3 months.
Primary outcome measure(s)
Safety variables — Every 6 months (± 2 months, as per centre practice) Catheter related infections (e.g. peritonitis, tunnel infections, exit site infection)
Safety variables — Every 6 months (± 2 months, as per centre practice) Non-infectious complications
Safety variables — Every 6 months (± 2 months, as per centre practice) Biocompatibility (allergic reaction)
Safety variables — Every 6 months (± 2 months, as per centre practice) Identify new emerging risks
Safety variables — Every 6 months (± 2 months, as per centre practice) Monitor side effects
Safety variables — Every 6 months (± 2 months, as per centre practice) Catheter removal
Trial sites (2)
Facility
City
Region
Status
Klinikum Dortmund gGmbH
Dortmund
Germany
Recruiting
RCU- Renal Care Unit, Dr. med. Mario Gerrit Bohling
Wilhelmshaven
Germany
Recruiting
More Fresenius Medical Care Deutschland GmbH trials in Germany
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.